T. Rowe Price Associates
KNSA icon

T. Rowe Price Associates’s Kiniksa Pharmaceuticals KNSA Stock Holding History

T. Rowe Price Associates’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,755
Closed -$373K – 3104
2025
Q1 		$373K Buy
16,755
+1,644
+11% +$33.8K ﹤0.01% 2375
2024
Q4 		$299K Buy
15,111
+2,881
+24% +$65.8K ﹤0.01% 2513
2024
Q3 		$306K Buy
12,230
+348
+3% +$8.48K ﹤0.01% 2467
2024
Q2 		$222K Buy
+11,882
New +$223K ﹤0.01% 2553
2021
Q3 		– Sell
-13,231
Closed -$184K – 2966
2021
Q2 		$184K Buy
+13,231
New +$201K ﹤0.01% 2749

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return